Theorem Clinical Research

R&D Trends

Dako, Ono Pharmaceutical to collaborate on diagnostic test Opdivo

Wednesday, February 18, 2015 11:45 AM

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical, headquartered in Osaka, Japan, have partnered to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

More... »

Quest Diagnostics

Janssen R&D launches three new research platforms

Friday, February 13, 2015 11:35 AM

Janssen R&D, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has launched three new research platforms focused on disease prevention, disease interception and the microbiome—areas of transformational medical innovation that are expected to change the healthcare landscape. The new teams will collaborate closely with Janssen’s five therapeutic areas as well as external partners, to underpin ongoing research and propel scientific knowledge.

More... »


Affinivax, PATH collaborate on pneumococcal disease vaccine candidate

Friday, February 13, 2015 11:30 AM

Affinivax, a Cambridge, Mass.-based biotechnology company dedicated to developing novel vaccines, has entered into a collaboration with PATH, a global health nonprofit organization, to advance the company’s lead vaccine candidate for Streptococcus pneumoniae (pneumococcus). The partnership includes funding from PATH to support product development, preclinical testing and manufacturing, with the goal to qualify and select a final development candidate to advance toward clinical testing.

More... »

UT Southwestern to establish Center for Heavy Ion Radiation Therapy

Thursday, February 12, 2015 01:07 PM

UT Southwestern Medical Center is leading a Texas consortium of researchers to establish the country's first National Center for Heavy Ion Radiation Therapy that could provide clinical care and research using heavy particles for innovative new cancer treatments.

More... »

Thiel Foundation's Breakout Labs selects three early-stage companies for funding

Thursday, February 12, 2015 01:05 PM

Breakout Labs, a seed-stage revolving fund operating out of the nonprofit Thiel Foundation in San Francisco, has announced three new companies have been selected for funding. These companies include Neumitra, Ion Dx, E3XBio.

More... »

Advaxis, Incyte collaborate on early stage cervical cancer immunotherapies

Thursday, February 12, 2015 01:04 PM

Advaxis, a Princeton, N.J.-based clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). Incyte is a pharmaceutical company based in Alapocas, Del.

More... »

Voyager Therapeutics, Genzyme collaborate on CNS disorders

Thursday, February 12, 2015 01:01 PM

Voyager Therapeutics, a gene therapy company headquartered in Cambridge, Mass. developing treatments for diseases of the central nervous system (CNS), and Genzyme, a Sanofi company and gene therapy pioneer, have announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders. The collaboration will leverage Genzyme’s long-standing commitment and experience in adeno-associated virus (AAV) gene therapy and Voyager’s AAV product engine to develop breakthrough therapies for patients suffering from severe CNS disorders.

More... »

Cellular Biomedicine Group, Chinese PLA General Hospital ink agreement

Wednesday, February 11, 2015 12:38 PM

Cellular Biomedicine Group, a Palo Alto, Calif.-based biomedicine company engaged in the development of cellular therapies for degenerative and cancerous diseases, has acquired Chinese PLA General Hospital's (PLAGH, Beijing, also known as 301 Hospital) Chimeric Antigen Receptor T cell (CAR-T) therapy; its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor's (EGFR or HER1) Immuno-Oncology patents (all pending); and phase I/II clinical data of the aforementioned therapies and manufacturing knowledge.

More... »

International GPCR Consortium adds Novo Nordisk and Merck

Wednesday, February 11, 2015 12:34 PM

The GPCR Consortium, an international nonprofit collaboration that comprises academic research institutes in the U.S. and China and major pharma companies around the world, has announced Novo Nordisk and Merck as new members. The companies join AmgenSanofi and Ono in the GPCR Consortium. The research funded by the GPCR Consortium currently is conducted at the Bridge Institute at the University of Southern CaliforniaShanghai Institute of Materia Medica and the iHuman Institute at ShanghaiTech University.

More... »

ALK, bioCSL partner for allergy tablets

Wednesday, February 11, 2015 12:30 PM

ALK and bioCSL have entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as Grazax in Europe and Grastek in North America), and its adrenaline auto-injector, Jext. ALK will be responsible for product supply and bioCSL will undertake registration and commercialization of the products.

More... »

AiCure
CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs